Evolus - Likuiditas cepet EOLS

The market price action of Evolus, Inc. (EOLS) reflects the dynamics of the quick ratio, which stands at 1.25. Stability of clinic supplies is ensured by an extensive network of cold-storage warehouses that minimize customs risks. Evolus, Inc. (EOLS) generates revenue from the sale of advanced neurotoxins for cosmetic rejuvenation. Meanwhile, final performance metrics are impacted by high advertising budgets and a potential decline in consumer spending during inflationary periods.

This indicator compares cash and accounts receivable against short-term liabilities, completely excluding inventories from the calculation. The metric determines the business's ability to instantly settle debts without liquidating warehouse stock, identifying risks of cash flow gaps. For Evolus, Inc. (EOLS), this is critical, as the turnover of expensive neurotoxins can be slow. Analysis of the resulting quick ratio confirms the financial stability of the aesthetic medicine model.